Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20681295 | 0.96 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30120869 | 0.96 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL25202453 | 0.96 | CDC25B (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30635627 | 0.96 | CDC25B (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1760720 | 0.91 | TSHR (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30291781 | 0.83 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28303303 | 0.81 | CDC25B (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21810674 | 0.80 | ADCY6 (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1535914 | 0.78 | MAPT (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3208997 | 0.78 | POLB (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150291-A1 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | claimed |
| EP-3867231-B1 | NOVEL PROCESSES | INFLAZOME LTD (IE) | 2024-05-01 | — | — | EP | claimed |
| EP-4359385-A2 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | claimed |
| WO-2021048809-A9 | NOVEL SUBSTITUTED SULFOXIMINE DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2023-01-19 | — | — | WO | claimed |
| WO-2022268935-A2 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-29 | — | — | WO | claimed |
| EP-4027986-A1 | NOVEL SUBSTITUTED SULFOXIMINE DERIVATIVES | Cadila Healthcare Limited (IN) | 2022-07-20 | — | — | EP | claimed |
| CN-113387831-A | Amide compound and application thereof in preparation of neuroinflammation inhibitor | 苏州大学 | 2021-09-14 | — | — | CN | claimed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2025104244-A1 | METHODS OF PREPARING UREA DERIVATIVES | NodThera Limited (GB) | 2025-05-22 | — | — | WO | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| CN-115894478-B | Novel pyridopyrazole heterocyclic compound and application thereof | 杭州民生药物研究院有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2025-03-06 | — | — | US | disclosed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1270554-A1 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6433009-B1 | TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| US-3884986-A | Catalytic conversion of polycyclic aromatic hydrocarbons in the presence of hydrogen | SUN VENTURES INC | 1975-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | GRIN2D 4323/4885GRIN3B 3814/4885GRIN1 3778/4885 |
| US-20240150291-A1 | PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | GRIN2D 1953/4885GRIN3B 1812/4885GRIN1 878/4885 |
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | NLRP3, XIAP, NLRP1 | GRIN2D 4353/4885GRIN3B 3793/4885GRIN1 2590/4885 |
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | GRIN2D 3462/4885GRIN3B 3916/4885GRIN1 607/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | GRIN2D 1574/4885GRIN3B 3903/4885GRIN1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.